M
Margaret McAlary
Researcher at Novartis
Publications - 8
Citations - 3523
Margaret McAlary is an academic researcher from Novartis. The author has contributed to research in topics: Omalizumab & Immunoglobulin E. The author has an hindex of 8, co-authored 8 publications receiving 3332 citations.
Papers
More filters
Journal ArticleDOI
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Andre van As,Niroo Gupta +7 more
TL;DR: The addition of omalizumab to standard asthma therapy reduces asthma exacerbations and decreases inhaled corticosteroid and rescue medication use.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Treatment of Childhood Asthma With Anti-Immunoglobulin E Antibody (Omalizumab)
Henry Milgrom,William E. Berger,Anjuli Nayak,Niroo Gupta,Stephen Pollard,Margaret McAlary,Angel Fowler Taylor,Patricia Rohane +7 more
TL;DR: Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids, and cause a down-regulation of FcepsilonRI receptors on basophils.
Journal ArticleDOI
Effect of Omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial
Thomas B. Casale,John J. Condemi,Craig LaForce,Anjuli Nayak,Michael Rowe,Marc Watrous,Margaret McAlary,Angel FowlerTaylor,Amy Racine,Niroo Gupta,Robert B. Fick,Giovanni Della Cioppa +11 more
TL;DR: Omalizumab decreased serum free IgE levels and provided clinical benefit in patients with seasonal allergic rhinitis as mentioned in this paper in a dose-dependent fashion in patients aged 12 to 75 years.
Effect of Omalizumab on Symptoms of Seasonal Allergic Rhinitis
Thomas B. Casale,John J. Condemi,Craig LaForce,Anjuli Nayak,Michael Rowe,Marc Watrous,Margaret McAlary,Niroo Gupta,Robert B. Fick,Giovanni Della Cioppa +9 more
TL;DR: Omalizumab decreased serum free IgE levels and provided clinical benefit in a dose-dependent fashion in patients with seasonal allergic rhinitis andRhinitis-specific quality of life scores were consistently better in patients who received 300 mg of omalizuab than in those who received lower dosages or placebo and did not decline during peak season.